Posted in | News | Minerals | Mining

BHP Billiton Start Alumina Production at Brazillian Refinery Expansion

BHP Billiton today announced first production from the expansion of the Alumar alumina refinery in Brazil. The project, which involved upgrading the existing plant to eliminate bottlenecks and adding an extra line, is now more than 98% complete. Full mechanical completion is expected in September and the final ramp-up to full production will by the second half of the year.

The upgrade and expansion project will increase the output of the refinery by 2.0 million tons, from approximately 1.5 million metric tons to a total production capacity of 3.5 million metric tons per year for the Alumar Consortium. The Alumar Consortium is owned by Alcoa (54% share), BHP Billiton (36%) and Rio Tinto Alcan (10%).

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BHP. (2019, February 10). BHP Billiton Start Alumina Production at Brazillian Refinery Expansion. AZoM. Retrieved on November 24, 2024 from https://www.azom.com/news.aspx?newsID=18003.

  • MLA

    BHP. "BHP Billiton Start Alumina Production at Brazillian Refinery Expansion". AZoM. 24 November 2024. <https://www.azom.com/news.aspx?newsID=18003>.

  • Chicago

    BHP. "BHP Billiton Start Alumina Production at Brazillian Refinery Expansion". AZoM. https://www.azom.com/news.aspx?newsID=18003. (accessed November 24, 2024).

  • Harvard

    BHP. 2019. BHP Billiton Start Alumina Production at Brazillian Refinery Expansion. AZoM, viewed 24 November 2024, https://www.azom.com/news.aspx?newsID=18003.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.